ae37
Generic: immunotherapeutic peptide vaccine
ae37: developed by 2 companies. Updated within the last hour.
Development Pipeline (2)
| Company | Phase |
|---|---|
| GENEREX BIOTECHNOLOGY CORP (GNBT) | Phase 2 |
| NUGENEREX IMMUNO-ONCOLOGY, INC. (NGIO) | Phase 2 |
Get deeper analysis on ae37
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis